Benitec Reports Positive Interim BB-301 Phase 1b/2a Results
Benitec Biopharma reported positive interim Phase 1b/2a results for high-dose BB-301 and continued durable improvements for low-dose BB-301.
Story updates
12:04:49 PM UTC
SquawkNews
Benitec Biopharma Inc. reported positive interim Phase 1b/2a results for BB-301 in OPMD: both doses improved swallowing, 100% of treated patients were responders, and no Serious Adverse Events were reported. High dose showed greater improvements at 3 months.Material DetailsContext by AI AnalystThis…
12:13:18 PM UTC
SquawkNews
Benitec Biopharma reported positive interim Phase 1b/2a results for high-dose BB-301 and durable improvements with low-dose treatment, with all nine patients responding to date.Key Highlights:Original SEC Filing: Benitec Biopharma Inc. [ BNTC ] - 8-K - Oct. 28, 2026This is an AI-powered summary. It…